-
公开(公告)号:US07858666B2
公开(公告)日:2010-12-28
申请号:US12135571
申请日:2008-06-09
CPC分类号: C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译: 在体外直接抑制IRE-1α活性的化合物,其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病,并可用作单一药剂或联合疗法。
-
公开(公告)号:US08614253B2
公开(公告)日:2013-12-24
申请号:US12941530
申请日:2010-11-08
申请人: John Bruce Patterson , David Gregory Lonergan , Gary A. Flynn , Qingping Zeng , Peter V. Pallai
发明人: John Bruce Patterson , David Gregory Lonergan , Gary A. Flynn , Qingping Zeng , Peter V. Pallai
IPC分类号: A61K31/11
CPC分类号: C07C65/21 , A61K31/11 , A61K31/135 , A61K31/166 , A61K31/192 , A61K31/357 , A61K31/381 , A61K31/505 , A61K31/5375 , A61K31/5377 , C07C47/55 , C07C47/565 , C07C47/575 , C07C65/11 , C07C65/26 , C07C65/30 , C07C205/44 , C07C205/61 , C07C223/02 , C07C233/65 , C07C235/42 , C07C235/84 , C07C251/24 , C07C317/24 , C07C321/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/48 , C07D213/64 , C07D213/69 , C07D213/74 , C07D215/14 , C07D217/16 , C07D231/12 , C07D235/08 , C07D239/26 , C07D239/54 , C07D241/18 , C07D249/18 , C07D261/08 , C07D277/34 , C07D295/125 , C07D295/15 , C07D295/192 , C07D307/80 , C07D317/54 , C07D319/08 , C07D319/18 , C07D321/10 , C07D333/22 , C07D333/58 , C07D401/12 , C07D403/12 , C07D417/10 , Y02A50/389 , Y02A50/393
摘要: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
摘要翻译: 在体外直接抑制IRE-1α活性的化合物,其前药和药学上可接受的盐。 这样的化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病,并可用作单一药剂或联合疗法。
-
公开(公告)号:US20130116247A1
公开(公告)日:2013-05-09
申请号:US13639734
申请日:2011-04-05
申请人: Qingping Zeng , Andras Toro , John Bruce Patterson , Warren Stanfield Wade , Zoltan Zubovics , Yun Yang , Zhipeng Wu
发明人: Qingping Zeng , Andras Toro , John Bruce Patterson , Warren Stanfield Wade , Zoltan Zubovics , Yun Yang , Zhipeng Wu
IPC分类号: A61K31/366 , A61K31/496 , A61K31/5377 , C07D405/04 , A61K31/4025 , C07D405/10 , A61K31/453 , C07D417/04 , A61K31/427 , A61K31/4155 , C07D401/04 , A61K31/4433 , C07D409/04 , C07D311/94 , A61K45/06 , C07D311/20
CPC分类号: A61K31/366 , A61K31/343 , A61K31/352 , A61K31/37 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4155 , A61K31/4172 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/4433 , A61K31/4439 , A61K31/452 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D217/02 , C07D217/08 , C07D311/12 , C07D311/16 , C07D311/20 , C07D311/22 , C07D311/94 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D417/04 , Y02A50/389 , Y02A50/393
摘要: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
摘要翻译: 直接抑制体外IRE-1α活性的化合物,其前体药物和药学上可接受的盐。 这些化合物和前药可用于治疗与未折叠的蛋白质应答相关的疾病或者与调节的IRE1依赖性衰变(RIDD)相关的疾病,并可用作单一药物或联合疗法。
-
4.
公开(公告)号:US20110263647A1
公开(公告)日:2011-10-27
申请号:US13130255
申请日:2010-01-13
申请人: Qingping Zeng , Chester Chenguang Yuan , Guomin Yao , Xianghong Wang , Seifu Tadesse , David J. ST. Jean, JR. , Andreas Reichelt , Qingyian Liu , Fang-Tsao Hong , Nianhe Han , Christopher H. Fotsch , Carl D. Davis , Matthew P. Bourbeau , Kate S. Ashton , John G. Allen
发明人: Qingping Zeng , Chester Chenguang Yuan , Guomin Yao , Xianghong Wang , Seifu Tadesse , David J. ST. Jean, JR. , Andreas Reichelt , Qingyian Liu , Fang-Tsao Hong , Nianhe Han , Christopher H. Fotsch , Carl D. Davis , Matthew P. Bourbeau , Kate S. Ashton , John G. Allen
IPC分类号: A61K31/4709 , C07D417/14 , A61P35/00 , C07D417/04
CPC分类号: C07D417/14 , C07D417/04
摘要: The invention relates to thiazole compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
摘要翻译: 本发明涉及式I的噻唑化合物及其组合物,其用于治疗由蛋白激酶B(PKB)介导的疾病,其中变量具有本文提供的定义。 本发明还涉及这种噻唑化合物及其组合物治疗与异常细胞生长,癌症,炎症和代谢紊乱相关的疾病的治疗用途。
-
公开(公告)号:US07919514B2
公开(公告)日:2011-04-05
申请号:US12077633
申请日:2008-03-19
IPC分类号: A61K31/433 , C07D285/12
CPC分类号: C07D417/14 , C07D417/04 , C07D471/04
摘要: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
摘要翻译: 本发明涉及可用于治疗由蛋白激酶B(PKB)介导的疾病的噻二唑化合物。 本发明还涉及这种噻二唑化合物及其组合物在治疗与异常细胞生长,癌症,炎症和代谢紊乱相关的疾病状态中的治疗用途。
-
公开(公告)号:US07919504B2
公开(公告)日:2011-04-05
申请号:US12218523
申请日:2008-07-15
申请人: Qingping Zeng , Chester Chenguang Yuan , Guomin Yao , Xianghong Wang , Seifu Tadesse , Andreas Reichelt , Qingyian Liu , Matthew R. Lee , Xin Huang , Fang-Tsao Hong , Nianhe Han , Christopher H. Fotsch , Celia Dominguez , Matthew P. Bourbeau , John G. Allen
发明人: Qingping Zeng , Chester Chenguang Yuan , Guomin Yao , Xianghong Wang , Seifu Tadesse , Andreas Reichelt , Qingyian Liu , Matthew R. Lee , Xin Huang , Fang-Tsao Hong , Nianhe Han , Christopher H. Fotsch , Celia Dominguez , Matthew P. Bourbeau , John G. Allen
IPC分类号: A61K31/47 , C07D401/04
CPC分类号: C07D285/135 , C07D417/04 , C07D417/14 , C07D495/04
摘要: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
摘要翻译: 本发明涉及式I和式II的噻唑化合物及其用于治疗由蛋白激酶B(PKB)介导的疾病的组合物,其中变量具有本文提供的定义。 本发明还涉及这种噻唑化合物及其组合物治疗与异常细胞生长,癌症,炎症和代谢紊乱相关的疾病的治疗用途。
-
公开(公告)号:US20090270445A1
公开(公告)日:2009-10-29
申请号:US12378195
申请日:2009-02-11
申请人: Qingping Zeng , John G. Allen , Matthew P. Bourbeau , Celia Dominguez , Christopher H. Fotsch , Nianhe Han , Fang-Tsao Hong , Xin Huang , Matthew R. Lee , Aiwen Li , Qingyian Liu , James T. Rider , Seifu Tadesse , Andrew S. Tasker , Vellarkad N. Viswanadhan , Xianghong Wang , Kurt E. Weiler , George E. Wohlhieter , Guomin Yao , Chester Chenguang Yuan
发明人: Qingping Zeng , John G. Allen , Matthew P. Bourbeau , Celia Dominguez , Christopher H. Fotsch , Nianhe Han , Fang-Tsao Hong , Xin Huang , Matthew R. Lee , Aiwen Li , Qingyian Liu , James T. Rider , Seifu Tadesse , Andrew S. Tasker , Vellarkad N. Viswanadhan , Xianghong Wang , Kurt E. Weiler , George E. Wohlhieter , Guomin Yao , Chester Chenguang Yuan
IPC分类号: A61K31/427 , A61K31/437 , A61P35/00
CPC分类号: C07D417/04 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
摘要: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.
摘要翻译: 本发明涉及使用式I和式II的噻唑化合物及其组合物用于治疗由蛋白激酶B(PKB)介导的疾病,例如癌症和其它增殖性疾病,其中变量具有本文提供的定义。
-
公开(公告)号:US20080255145A1
公开(公告)日:2008-10-16
申请号:US12077633
申请日:2008-03-19
申请人: Holger Monenschein , James T. Rider , Guomin Yao , Qingping Zeng
发明人: Holger Monenschein , James T. Rider , Guomin Yao , Qingping Zeng
IPC分类号: A61K31/496 , C07D417/14 , C07D417/02 , A61K31/433 , C07D471/04 , A61K31/437
CPC分类号: C07D417/14 , C07D417/04 , C07D471/04
摘要: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
-
公开(公告)号:US08084479B2
公开(公告)日:2011-12-27
申请号:US12378195
申请日:2009-02-11
申请人: Qingping Zeng , John G. Allen , Matthew P. Bourbeau , Celia Dominguez , Christopher H. Fotsch , Nianhe Han , Fang-Tsao Hong , Xin Huang , Matthew R. Lee , Aiwen Li , Qingyian Liu , James T. Rider , Seifu Tadesse , Andrew S. Tasker , Vellarkad N. Viswanadhan , Xianghong Wang , Kurt E. Weiler , George E. Wohlhieter , Guomin Yao , Chester Chenguang Yuan
发明人: Qingping Zeng , John G. Allen , Matthew P. Bourbeau , Celia Dominguez , Christopher H. Fotsch , Nianhe Han , Fang-Tsao Hong , Xin Huang , Matthew R. Lee , Aiwen Li , Qingyian Liu , James T. Rider , Seifu Tadesse , Andrew S. Tasker , Vellarkad N. Viswanadhan , Xianghong Wang , Kurt E. Weiler , George E. Wohlhieter , Guomin Yao , Chester Chenguang Yuan
IPC分类号: A01N43/38 , A01N43/78 , A61K31/405 , A61K31/425 , C07D277/00
CPC分类号: C07D417/04 , C07D417/14 , C07D471/04 , C07D495/04 , C07D513/04
摘要: The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein.
摘要翻译: 本发明涉及使用式I和式II的噻唑化合物及其组合物用于治疗由蛋白激酶B(PKB)介导的疾病,例如癌症和其它增殖性疾病,其中变量具有本文提供的定义。
-
公开(公告)号:US07354944B2
公开(公告)日:2008-04-08
申请号:US11251846
申请日:2005-10-18
申请人: Qingping Zeng , Guomin Yao , George Erich Wohlhieter , Vellarkad N. Viswanadhan , Andrew Tasker , James Thomas Rider , Holger Monenschein , Celia Dominguez , Matthew Paul Bourbeau
发明人: Qingping Zeng , Guomin Yao , George Erich Wohlhieter , Vellarkad N. Viswanadhan , Andrew Tasker , James Thomas Rider , Holger Monenschein , Celia Dominguez , Matthew Paul Bourbeau
IPC分类号: A61K31/433 , A61K31/4725 , A61K31/416 , A61K31/4162 , C07D285/135 , C07D217/02 , C07D405/04 , C07D417/04 , C07D217/00
CPC分类号: C07D417/14 , C07D417/04 , C07D471/04
摘要: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
摘要翻译: 本发明涉及可用于治疗由蛋白激酶B(PKB)介导的疾病的噻二唑化合物。 本发明还涉及这种噻二唑化合物及其组合物在治疗与异常细胞生长,癌症,炎症和代谢紊乱相关的疾病状态中的治疗用途。
-
-
-
-
-
-
-
-
-